{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:54Z","timestamp":1790792634022,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Data on pregnancy outcomes following fetal exposure to disease\u2010modifying drugs (DMDs) in women with multiple sclerosis (MS) are sparse although growing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the Danish Multiple Sclerosis Registry were linked with nationwide registries enabling an investigation of adverse pregnancy outcomes in newborns of women with MS following fetal exposure to injectable first\u2010line treatments, dimethyl fumarate, glatiramer acetate, or natalizumab. Logistic regression models accounting for clustered data were used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for individual and composite adverse outcomes after adjusting for relevant covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1009 DMD\u2010exposed pregnancies were compared with 1073 DMD\u2010unexposed pregnancies as well as 91,112 pregnancies from the general population. No association of an increased risk of any perinatal outcome was found when comparing newborns with fetal exposure with the general population, including preterm birth (OR\u00a0=\u00a01.19, 95% CI\u00a0=\u00a00.86\u20131.64), small for gestational age (OR\u00a0=\u00a01.38, 95% CI\u00a0=\u00a00.92\u20132.07), spontaneous abortion (OR\u00a0=\u00a01.04, 95% CI\u00a0=\u00a00.84\u20131.27), congenital malformation (OR\u00a0=\u00a00.99, 95% CI\u00a0=\u00a00.68\u20131.45), low Apgar score (OR\u00a0=\u00a00.62, 95% CI\u00a0=\u00a00.23\u20131.65), stillbirth (OR\u00a0=\u00a01.05, 95% CI\u00a0=\u00a00.33\u20133.31), placenta complication (OR\u00a0=\u00a00.53, 95% CI\u00a0=\u00a00.22\u20131.27), and any adverse event (OR\u00a0=\u00a01.10, 95% CI\u00a0=\u00a00.93\u20131.30). Similar results were found when comparing DMD\u2010exposed pregnancies with DMD\u2010unexposed pregnancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to DMDs when compared with either DMD\u2010unexposed pregnancies or the general population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.15559","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T11:28:53Z","timestamp":1663068533000},"page":"162-171","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pregnancy outcomes after early fetal exposure to injectable first\u2010line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-2965","authenticated-orcid":false,"given":"Johanna Balslev","family":"Andersen","sequence":"first","affiliation":[{"name":"Danish Multiple Sclerosis Registry, Department of Neurology Copenhagen University Hospital\u2013Rigshospitalet  Glostrup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center, Department of Neurology Copenhagen University Hospital\u2013Rigshospitalet  Glostrup Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-5222","authenticated-orcid":false,"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Registry, Department of Neurology Copenhagen University Hospital\u2013Rigshospitalet  Glostrup Denmark"},{"name":"Danish Multiple Sclerosis Center, Department of Neurology Copenhagen University Hospital\u2013Rigshospitalet  Glostrup Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"EMA.European Medicines Agency \u2010 Find medicine \u2010 Aubagio http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002514\/human_med_001645.jsp&mid=WC0b01ac058001d124(accessed 10 April 2018)."},{"key":"e_1_2_10_3_1","unstructured":"EMA.EMA Mavenclad. Accessed February 9 2020.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/mavenclad\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1530\/ror.0.0040081"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/985646"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.209"},{"key":"e_1_2_10_7_1","unstructured":"HellwigK ThielS MeinlI et al.Long\u2010term exposure to natalizumab during pregnancy \u2010 a prospective case series from the German multiple sclerosis and pregnancy registry;2018. Abstract 204."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101961"},{"key":"e_1_2_10_9_1","first-page":"1","article-title":"The Danish multiple sclerosis registry","volume":"11","author":"Magyari M","year":"2020","journal-title":"Brain Behav"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0356-1"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399957"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"e_1_2_10_14_1","unstructured":"Sundhedsdatastyrelsen.www.esundhed.dk.2019.http:\/\/end2019.esundhed.dk\/sundhedsregistre\/MFR\/Sider\/MFR06A.aspx"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2013.803739"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.98.1.141"},{"key":"e_1_2_10_17_1","unstructured":"EUROCAT Guide 1.4 and Reference Documents.2018.https:\/\/eu\u2010rd\u2010platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa326"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.12849"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09762-y"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420951072"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2016-079"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515623366"},{"issue":"15","key":"e_1_2_10_24_1","article-title":"Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters (P4.362)","volume":"90","author":"Hellwig K","year":"2018","journal-title":"Neurology"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516634872"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S278596"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-015-0033-1"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001114"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005067"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514546790"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0674-4"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005067"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7325-8"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2014-205387"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002746"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10134"},{"key":"e_1_2_10_37_1","first-page":"240","article-title":"The clinical use of corticosteroids in pregnancy","volume":"22","author":"Kemp MW","year":"2015","journal-title":"Hum Reprod Update"},{"key":"e_1_2_10_38_1","unstructured":"Neurologisk National Behandlingsvejledning. Dansk Neurologisk Selskab. Accessed December 2021.https:\/\/neuro.dk\/wordpress\/nnbv\/behandling\u2010af\u2010ms\u2010attak\/"},{"key":"e_1_2_10_39_1","unstructured":"F\u00f8dte og f\u00f8dsler (1997). Accessed October 3 2021.https:\/\/www.esundhed.dk\/home\/emner\/graviditetfoedsler og boern\/foedte og foedsler 1997."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001035"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.002"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.033"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.15559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T09:19:12Z","timestamp":1692523152000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/ene.15559"],"URL":"https:\/\/doi.org\/10.1111\/ene.15559","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2022-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}